Mylan

Notable Insider Buys of the Past Week: Mylan, Sonabank, Steak 'n Shake, U-Haul And More

Bulls & Bears Of The Week: GE, Netflix, Nike, Twitter And More

New Year's Benzinga Bulls & Bears: Apple, Disney, Netflix And More

Bulls & Bears Of The Week: GE, Netflix, Nike, Twitter And More

New Year's Benzinga Bulls & Bears: Apple, Disney, Netflix And More

Biotech Investors, Here's Your PDUFA Primer For October

Mylan's Stock Is No Longer A Buy According To Analysts At Argus

Biotech Investors, Here's Your PDUFA Primer For October

Mylan's Stock Is No Longer A Buy According To Analysts At Argus

How Does Mylan's $300 Choice Compare To Other Generic EpiPens?

Epipen's Profits Are Actually A Lot Higher Than Mylan Originally Told Congress

Mylan Recent News

Mylan's CEO Showed 'Very Little Empathy,' Bill George Says

Mylan Investors Should Be Asking Where (And Who) Robert Coury Is

MannKind Is 'Making Progress' On Its Alternative To Mylan's EpiPen, Report Says

Mylan CEO: The Healthcare System Is Broken

Mylan Cuts EpiPen Costs By Up To 50% Via Coupon

Have You Heard About This Generic EpiPen Maker?

Generic Drugs In The Earnings Spotlight: Mylan And Valeant Pharmaceuticals

Mylan Is 'Comfortable Moving Forward' With Acquisition Of Sweden-Based Meda

Barron's Picks & Pans: Martin Marietta Materials, Deutsche Bank, Mylan And More

Shares Of Mylan Slightly Higher Following Launch Of Generic Drug

Mylan-Perrigo Buyout Offer: What's Next?

Theravance Just Lost Its Catalyst

Is Mylan's FDA Warning Letter Worth Worrying About?

Report: Mylan Could See Sweetened Bid From Teva Pharmaceutical

What's Gabelli Saying About Teva Now?

And The Winner From The Mylan-Perrigo Merger Is... Teva?

JPMorgan Says Mylan Has 3 Paths To Upside

S&P 500 Falls To Two-Month Low, Dow Drifts Further Away From The 17,000 Mark

5 Drug Companies Profiting From Generics

Dow Sets New Intraday High; Citigroup Impresses With Earnings

Earnings Expectations For The Week Of April 28: Big Oil, Big Pharma And More

Market Wrap For April 4: Dow Suffers Triple Digit Point Loss, Nasdaq Continues To Underperform

Pfizer's Blockbuster Drug Celebrex To Lose Patent Protection